Corticotrophin Releasing Factor 2 for the Treatment of Worsening Heart Failure (WHF) - The CRAFT-WHF Study
Corteria Pharmaceuticals
Summary
This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
Description
This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the dose-dependent effects of 3 doses of the corticotropin-releasing factor type 2 (CRF2) peptide agonist, COR-1167, in subjects with WHF, defined as subjects requiring urgent administration of intravenous (i.v.) diuretics due to worsening of signs and symptoms of heart failure (HF) associated with volume overload
Eligibility
- Age range
- 18–85 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Signed written informed consent * Heart failure hospitalization (HFH) during previous 12 months * Prescribed an oral loop diuretic for at least 1 month preceding the index event * NT-proBNP ≥1,000 pg/mL or BNP ≥250 pg/mL * Requires treatment with i.v. diuretics for volume overload * At least 1 risk factor for diuretic resistance * Admitted to the hospital not more than 48 hours prior to randomization Exclusion Criteria: * Index event primarily triggered by an acute event (e.g. AMI, PE, arrhythmia) * Requirement for i.v. inotropic therapy or i.v. vasodilators, mechanica…
Interventions
- DrugCOR-1167
28-day treatment
- DrugPlacebo
28-day treatment
Locations (55)
- Indiana University Health Methodist HospitalIndianapolis, Indiana
- Wayne State University - Detroit Receiving HospitalDetroit, Michigan
- Wayne State University - Sinai Grace HospitalDetroit, Michigan
- Cone Health Moses Cone HospitalGreensboro, North Carolina
- NC Heart and Vascular Research, LLCRaleigh, North Carolina
- Ohio State UniversityColumbus, Ohio